Status: Recruiting
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with NAFLD. Additionally, the trial will conduct preliminary observations on the efficacy of B1344, aiming to provide early proof of concept for B1344 as a therapeutic agent for NASH.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Tasly Biopharmaceuticals Co., Ltd.Updated: Aug 19, 2025Locations: 5
Eligibility criteria
Chinese patients aged between 18 and 75 years; [+8]
Liver biopsy, or clinical diagnosis of cirrhosis based on clinical presentation,... [+33]